The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2024(SUPPLMENT) Evaluating the Neuroprotective Factor REST as a Target for Parkinson’s Disease
Study Rationale: Studies have shown that a regulatory factor called REST could promote the survival of neurons in neurodegenerative conditions. This factor is produced in greater quantities with age...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2024Enhancing Removal of Damaged Mitochondria in Neurons by Inhibiting the Enzyme Usp8
Study Rationale: Parkinson’s disease (PD) has long been associated with mitochondrial dysfunction. Perturbation of these subcellular structures can lead to the release of reactive oxygen species (ROS)...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Development of Novel LRRK2 Inhibitors for the Treatment of Parkinson’s Disease
Study Rationale: Inhibitors of the LRRK2 protein offer promise as a therapy for Parkinson’s disease (PD). The leading inhibitors currently under development, the so-called Type 1 kinase inhibitors...
-
Research Grant, 2024Funding Support 2024-2026 for Critical Path Clinical Outcome Assessment Experts
Study Rationale: To evaluate treatments in ways that are meaningful to people with Parkinson’s disease (PD), we need to identify measurements that reflect how people with early PD function and feel...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biomarkers, 2024Development and Validation of a Sensitive Method for Measuring PRKN
Study Rationale: Mutations in the genes encoding PRKN and PINK1 are associated with Parkinson’s disease (PD). PINK1 and PPKN proteins work together to mediate the degradation of damaged mitochondria...
-
Research Grant, 2024Assessment of Longitudinal Imaging Using Radiolabeled AV-133 in Early and Prodromal Parkinson’s Disease
Study Rationale: The clinical phase of Parkinson’s disease (PD) is preceded by a prodromal phase of progressing neurodegeneration that can last many years. Imaging markers such as radiolabeled AV-133...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.